You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
No matches

96 search results for: symptoms

Assessing EoE: Assessing <b>Symptoms</b> in Patients With EoE
expert video

Assessing EoE: Assessing Symptoms in Patients With EoE

Gastroenterology
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
View more
Most Burdensome <b>Symptoms</b> Rated by PN Patients
expert video

Most Burdensome Symptoms Rated by PN Patients

Dermatology
Dr. Chovatiya discusses the impact of pruritus on patients with PN.
View more
Type 2 Inflammation Contributes to the Signs and <b>Symptoms</b> of AD and PN
expert video

Type 2 Inflammation Contributes to the Signs and Symptoms of AD and PN

Dermatology
The impact of type 2 inflammation, neuroimmune axis dysfunction, and skin tissue on the signs and symptoms of atopic dermatitis and prurigo nodularis.
View more
Beyond the Signs ​and <b>Symptoms</b>: ​The Developmental Burden of AD in Children
expert video

Beyond the Signs ​and Symptoms: ​The Developmental Burden of AD in Children

Dermatology
Highlights from the ESPD 2023 ADVENT symposium: Exploring burden and comorbidities associated with moderate-to-severe atopic dermatitis in children.
View more
Importance of Assessing Key Disease Domains in EoE Infographic
Infographic

Importance of Assessing Key Disease Domains in EoE Infographic

Gastroenterology
Learn about the importance of assessing key disease domains in EoE by focusing on symptoms, QoL, endoscopy, and histology.
View more
UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?
expert video

UEGW 2024 | WHAT Can Be Used to Monitor Treatment Response in EoE and WHEN?

Gastroenterology
Dr. Milli Gupta emphasizes the need to regularly monitor multiple disease domains when assessing treatment response, not just EoE symptoms.
View more
Esophageal Dilation Does Not Impact Underlying Inflammation in EoE
expert video

Esophageal Dilation Does Not Impact Underlying Inflammation in EoE

Gastroenterology
Dr. Evan Dellon discusses why esophageal dilation improves symptoms but does not address the underlying histology or disease activity in EoE.
View more
The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)
Infographic

The Role of Type 2 Inflammation in Chronic Spontaneous Urticaria (CSU)

Dermatology
A summary infographic capturing how type 2 inflammation contributes to pathological processes leading to CSU signs and symptoms.
View more
ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?
Podcast

ADVENT On Air | Dysphagia in EoE: How Can You See Beyond Patients’ Adaptive Behaviors?

Gastroenterology
Learn from Dr. Hirano and Dr. Marcon as they discuss how to unmask EoE symptoms that may be hidden by patients' coping mechanisms.
View more
What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?
expert video

What role does IL-4 and IL-13 have in driving Type 2 inflammatory skin disease (AD, PN, CSU)?

Dermatology
Dr. Oscar Palomares explains that IL-4 and IL-13 are crucial cytokines in type 2 inflammation, playing both unique and overlapping roles, including T cell expansion and contributing to clinical symptoms in chronic diseases.
View more
CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients
interactivity

CRSwNP Significantly Affects the Quality of Life of CRSwNP Patients

Rhinology
Explore the factors that contribute to the significant burden of CRSwNP on patient quality of life.
View more
Adaptive Behaviors in EoE Infographic
Infographic

Adaptive Behaviors in EoE Infographic

Gastroenterology
Learn how to recognize adaptive eating behaviors in patients with EoE and why it is important for assessment and management.
View more

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: AustraliaChange country/region